isomethyleugenol has been researched along with Neurofibromatosis 1 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dombrowski, A; Fischer-Huchzermeyer, S; Harder, A; Mautner, VF; Stahn, V; Streubel, A; Wilke, G | 1 |
| Nakagawa, H; Nobeyama, Y | 1 |
| Coulter-Mackie, MB; Rodenhiser, DI; Singh, SM | 1 |
3 other study(ies) available for isomethyleugenol and Neurofibromatosis 1
| Article | Year |
|---|---|
MEK inhibitors enhance therapeutic response towards ATRA in NF1 associated malignant peripheral nerve sheath tumors (MPNST) in-vitro.
Topics: Animals; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Gene Expression Profiling; Humans; MAP Kinase Kinase Kinases; Methylation; Neurilemmoma; Neurofibromatosis 1; Protein Kinase Inhibitors; Rats; Signal Transduction; Tretinoin | 2017 |
MAGEA3 methylation status is associated with prognosis of malignant peripheral nerve sheath tumor and with neurofibroma type in neurofibromatosis type 1.
Topics: Antigens, Neoplasm; CpG Islands; DNA Methylation; Humans; Kaplan-Meier Estimate; Methylation; Neoplasm Proteins; Nerve Sheath Neoplasms; Neurofibroma; Neurofibromatosis 1; Prognosis; RNA, Messenger; Treatment Outcome | 2016 |
Evidence of DNA methylation in the neurofibromatosis type 1 (NF1) gene region of 17q11.2.
Topics: Base Sequence; Chromosomes, Human, Pair 17; DNA; Genes, Neurofibromatosis 1; Genetic Linkage; Genetic Markers; Humans; Methylation; Molecular Sequence Data; Neurofibromatosis 1; Polymerase Chain Reaction; Restriction Mapping | 1993 |